Government
Would You Take Weed and Magic Mushrooms Together in One Pill? – Doctors Working at CaaMTech on New Medical Breakthrough
A new medicl patent may roll cannabis and psilocybin into one pill for mental health patients
Researchers Aim To Combine Psilocybin and Cannabis Into Single Medical Treatment
According to a product patent from the renowned marijuana laboratory, CaaMTech, substantial strides have been made in developing a comprehensive treatment that combines cannabinoids and psilocybin for treating both physical and mental health concerns.
Located in Issaquah, Washington, less than 20 miles southeast of Seattle, CaaMTech is aggressively researching the interactions between these two chemicals as well as the potential effects on physical and mental health.
The initial stages of their enhanced psilocybin-cannabinoid product development are presently underway.
This patent advancement comes at a time when genetic data on cannabis and psilocybin is becoming more widely available, opening up possibilities for investigating novel ways these two substances might interact, potentially leading to the development of novel commercial products.
For instance, the use of cannabis and psilocybin together has shown to be effective in shrinking tumors in patients with breast cancer, as was the case in the case of a 49-year-old woman.
Researchers concluded as a result of this discovery that there is growing anecdotal and empirical evidence that supports the therapeutic effects of cannabinoids and psychedelics in preventing the growth of tumors and acting as palliative medicine to ease the pain and emotional distress brought on by cancer and chemotherapy.
Incorporating psilocybin with a minor cannabinoid like cannabichromene (CBC), abundant in the cannabis plant, may help researchers create a comprehensive treatment for inflammation and severe mental health issues.
The president and CEO of the Canadian cannabis business Hexo Corp., Charlie Bowman, reaffirmed the viability of this strategy by saying, “That most certainly can be done.” He added that while CBC is difficult to produce and expensive to synthesise, it may be combined with psilocybin mushrooms to provide a more cost-effective alternative to a broader spectrum of clients. Making a water-soluble version of CBC and mixing it with mushrooms could result in one possible way to consume it: as tea.
Cannabis-assisted psychedelic treatment is currently being used at the Center for Medicinal Mindfulness in Boulder, Colorado. It is run by Daniel McQueen, author of “Psychedelic Cannabis” and executive director. This entails facilitating private cannabis and ketamine psychedelic experiences under medical supervision, including classes, personalised coaching, guided meditation sessions, and community support.
McQueen concurred that creating a psilocybin-cannabis tablet or other combo substance is possible. He did point out, though, that cannabis by itself can already generate psychedelic states; other psychedelics are not required. We frequently use cannabis as a psychedelic for the same reasons that people seek out psilocybin and other medications, he went on to say.
Imagine a three-hour DMT-level psychedelic experience with MDMA’s emotional support and the capacity to retain your sense of autonomy, he continued. In this instance, McQueen was alluding to the hallucinogen dimethyltryptamine, demonstrating how psychedelic cannabis may be able to produce a comparable experience.
This is the range of potential being investigated with psychedelic marijuana.
Different Hurdles to the Combination
There are many difficulties in creating a combination of chemicals that must be overcome.
Different brain receptors are affected differently by psychedelics and cannabis. While cannabinoids like THC largely bind to the CB1 receptor, CBC and THC mostly bind to the CB2 receptor. However, psychedelics like psilocybin bind to the 5-HT2A serotonin receptors predominantly.
The cannabinoid CBD, however, may also interact with serotonin receptors, according to a study. Interestingly, serotonin and a CB2 cannabinoid receptor can work together to accomplish things neither receptor can do independently.
For instance, ischemia in neonatal pigs was the subject of a 2022 study by Spanish researchers who discovered that CBD activates a serotonin receptor with neuroprotective properties. The study suggests that a large portion of the neuroprotective effects of CBD are likely due to the stimulation of the 5-HT1A receptor, one of the three serotonin receptors to which psilocybin interacts.
Medical and Curative Implications
The medical marijuana community is growing more and more enthused as they become aware of the potential of the combo substance.
For instance, patients with breast cancer have shown a substantial tumor reduction when cannabis and psychedelics are combined.
Researchers at the University of Miami are also investigating a single pill containing CBD and psilocybin as a potential treatment for traumatic brain damage and PTSD.
In addition, a new survey-based study reveals that using cannabis and psychedelics together may increase the therapeutic advantages of doing so, indicating possible receptor target overlap.
According to the Centre for Psychedelic Research at Imperial College London, concurrent cannabis usage may intensify the positive psychological benefits connected with psychedelics. Based on survey responses from 321 participants from 40 different nations, the researchers concluded by comparing the subjective effects of psychedelics and cannabis, such as euphoria, changed time perception, increased sensory perception, and improved associative thinking.
Although the molecular mechanisms behind the synergistic effects of cannabis and psychedelics were not investigated in the current investigation, the findings strongly support their presence.
Although serotonergic psychedelics and cannabis have different modes of action, the Imperial researchers say that recent research has suggested that there may be some receptor target overlap between these two drug classes.
Similarities between cannabis and psychedelics
Research is still being done on the fascinating connection between cannabis and psychedelics; some results point to possible overlaps.
For example, recently found cannabinoids have shown the capacity to provide a stronger and more psychedelic experience, perhaps making them acceptable for psychedelic-assisted treatment without additional psychedelics.
THC-O, sometimes called THC acetate ester, is an example of a synthetic cannabinoid produced through chemical synthesis. Due to its powerful and intoxicating properties, this substance is relatively new and has attracted interest. Consumer reports indicate that THC-O produces more psychedelic or spiritual psychoactivity than other cannabinoids.
THCP, a recently discovered cannabinoid, has the potential to be 33 times more potent than THC. However, the specific effects of THCP on humans, including its potential to surpass psychedelics in potency and therapeutic applications, remain unknown. Nevertheless, ongoing research suggests that THCP could be a significant component in certain cannabis strains. Further studies are necessary to comprehend the properties and implications of this promising cannabinoid fully.
According to a 2019 study by Italian researchers, THCP should be added to the list of key phytocannabinoids to properly evaluate the pharmacological effects of cannabis extracts given to patients. According to the researchers, the finding of this powerful phytocannabinoid with THC-like qualities may shed light on some pharmacological characteristics that cannot all be attributable to delta-9 THC.
Additionally, research is being done to create psychedelics with antidepressant properties without causing hallucinations. The University of North Carolina School of Medicine’s Dr Bryan Roth and his research group have created a substance that, when administered to mice, targets the same brain regions as psychedelic drugs, producing long-lasting antidepressant effects without the psychedelic side effects.
Dr Roth is still dubious about the viability of a molecule that combines psychedelics and cannabis, though. He argues that while psychedelics boost activity in some neurons, cannabis usually lowers neuronal activity throughout the brain. As a result, these chemicals’ effects are vastly dissimilar.
Bottom Line
There is significant interest in investigating the use of cannabis and psychedelics together for therapeutic and medical purposes, according to ongoing research and breakthroughs. The possible advantages include treating inflammation and mental health conditions, decreasing tumors, and comforting relief. Despite the difficulties in developing a combination chemical, researchers are upbeat about the viability and affordability of such a medicine. Even though psychedelics and cannabis interact with brain receptors differently, data points to possible overlap, which supports the idea that mixing these drugs may have synergistic effects. More study is necessary to comprehend the molecular pathways completely and appreciate the medical ramifications of this combination.
Corruption
Vigilance Arrests Officials After Bribery Complaints at Supply Office
HARIDWAR, Uttarakhand — Officials from the Dehradun-based Vigilance Department have arrested Haridwar District Supply Officer Shyam Arya and two other employees on charges of accepting a bribe of ₹50,000, authorities confirmed. The arrests took place during a planned operation after investigators laid a trap at the District Supply Office in response to repeated complaints from the public.
According to vigilance sources, the accused were caught “red-handed” while receiving the alleged bribe, reportedly demanded in exchange for official services within the department. The operation, coordinated from the state capital of Dehradun, underscores the department’s commitment to tackling corruption.
Complaints That Triggered the Operation
The arrests followed months of complaints alleging that officials at the Haridwar District Supply Office were routinely soliciting illegal payments for government services. These included the issuance of ration cards, approvals for licenses, and other administrative clearances under the public distribution system.
Vigilance officials said preliminary verification of the complaints indicated a recurring pattern rather than isolated incidents. Following this assessment, the department used a standard anti-corruption tactic of laying a trap to obtain direct evidence of bribe solicitation and acceptance.
Inside the Supply Office
After the arrests, vigilance teams established a presence inside the office, sealing parts of the premises while examining files and records. Investigators are reviewing documentation related to recent approvals and transactions to determine whether the alleged bribery was systemic.
The accused are also being questioned to identify potential accomplices and to ascertain whether accepting bribes was a routine practice. Officials noted that the investigation could expand depending on findings from the document review and interrogations.
A Broader Anti-Corruption Push
The case has drawn attention across Uttarakhand’s administrative machinery, particularly within the Supply Department, which plays a vital role in delivering welfare services. Vigilance officials said the arrests reflect a “zero-tolerance” approach toward corruption and warned that similar operations will continue wherever credible complaints arise.
The state’s anti-corruption drives have intensified in recent months, emphasizing both deterrence and accountability. While the investigation in Haridwar remains in its early stages, officials say it highlights the risks faced by public servants accused of exploiting their positions and the growing willingness of enforcement agencies to act on citizen complaints.
Business
A Tipping Point for Cannabis: President Trump Champions CBD & Cannabis Science on Truth Social
When the President of the United States shares a video about the life changing potential of hemp derived CBD on his personal social media platform, it is more than news, it is a cultural shift.
For decades our government lied to us about cannabis. It demonized the plant, waged war on its users, and filled prisons while allowing pharmaceutical companies to flood the nation with addictive and deadly drugs. For over a century we have been fighting uphill, not just for legalization, but for truth, for science, and for the right to heal ourselves naturally.
Now in 2025, the most powerful political figure on Earth is using his own voice and platform to talk about the endocannabinoid system and the science backed benefits of CBD. That is monumental. It is validation for everyone who has fought, been arrested, been silenced, and been dismissed for telling this truth. The President’s video post is already being described as a pivotal moment in cannabis history, and President Trump CBD Cannabis Science Truth Social is trending across platforms as advocates celebrate the breakthrough.
The Science Behind the Endocannabinoid System
The video begins by introducing something most people, including many doctors, still know little about, the endocannabinoid system. Discovered in the 1990s, the ECS is a network of receptors and signaling molecules that works as the body’s master regulator, coordinating communication between major systems like the nervous, immune, cardiovascular, and digestive systems.
The roots of this discovery go back much further. CBD was first isolated in 1940 by American chemist Roger Adams, but it was Dr. Raphael Mechoulam, an Israeli organic chemist, who fully elucidated the chemical structure of CBD and identified its stereochemistry in the 1960s. His pioneering work not only opened the door to modern cannabinoid science but also earned him the title “Godfather of Cannabis Research.” It was this foundation that led to the identification of the endocannabinoid system itself decades later, revealing how cannabinoids interact with our physiology on a fundamental level.
The ECS is now widely recognized as a vital part of human biology, with extensive research supported by the National Institutes of Health. When functioning properly, the ECS acts like the conductor of an orchestra, ensuring every section plays in harmony. As we age, the system weakens. That imbalance is linked to inflammation, chronic pain, cognitive decline, sleep problems, and many other conditions associated with aging.
Mainstream medicine often addresses these issues with pharmaceutical band aids, dangerous and addictive drugs that treat symptoms rather than root causes. Lifestyle changes such as diet and exercise help, but they only partially support the ECS and do so slowly over time.
Hemp Derived CBD: A Game Changer for Aging
Here is where the science gets exciting. As the video explains, the ECS can be restored much more quickly with hemp derived CBD. Strengthening this system naturally helps the body regain balance, reducing pain, improving sleep, lowering stress, slowing disease progression, and even extending healthy lifespan.
It is not theoretical. One in five seniors is already using CBD to manage pain, arthritis, cancer symptoms, sleep disorders, Alzheimer’s, and more. Despite decades of research and acknowledgment from institutions like the National Institutes of Health, most physicians receive no training on the ECS. There are still no FDA standards for CBD products on the market. If that were the case for any other class of medicine, it would be considered malpractice.
The World Health Organization has confirmed CBD’s excellent safety profile and non addictive nature in its critical review report. The result is that millions of older Americans are suffering unnecessarily when a safe and natural solution exists.
Hemp derived CBD is a powerful first step in restoring balance to the endocannabinoid system, but it is only part of the picture. Research shows that full spectrum cannabis extracts, which include a broader range of cannabinoids and terpenes, can work even more effectively. Complete concentrated cannabis oil, containing the full spectrum of natural endocannabinoids, may deliver the most profound results for certain patients. Expanding access to these therapies will be essential if we want to unlock the full healing potential of this plant.
The Economic and Social Impact
The video cites a powerful figure. A PricewaterhouseCoopers analysis estimates that fully integrating cannabis into the healthcare system could save the United States nearly 64 billion dollars annually. These savings reflect reduced pharmaceutical dependency, fewer hospitalizations, improved chronic disease outcomes, and enhanced quality of life for aging Americans. You can read more about PwC’s research on healthcare innovation here.
It is a financial argument, but it is also a moral one. Why should our elders endure pain, anxiety, and cognitive decline when nature has given us tools to help them live longer, happier, and healthier lives?
A Call to Action: Finish What the Farm Bill Started
The message concludes by crediting the 2018 Farm Bill, championed by President Trump, for legalizing hemp and laying the groundwork for today’s CBD market. The Farm Bill was just the first step.
Now the call is for bold next moves.
- Educate doctors about the endocannabinoid system
- Include CBD under Medicare coverage
- Provide clear federal standards for CBD quality and dosing
These steps would constitute the most significant senior health reform in modern history, one that would transform aging and cement a powerful legacy for any administration that makes it happen.
What This Means for Future Cannabis Medicine
For those of us who have been in the cannabis community for decades, this is not just another news story. It is a signal that our movement is winning. A conversation that was once criminalized and censored is now being amplified by the President of the United States on his own platform.
It means the science is undeniable. It means the truth can no longer be buried. It means the wall of prohibition is cracking, not just legally, but culturally, scientifically, and politically.
It also means that everything we have been fighting for at 420 Magazine since 1993, education, access, healing, and justice, is finally moving full steam ahead. The President Trump CBD Cannabis Science Truth Social moment is proof that science and policy are finally converging.
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
